- Home
- KZIA vs KXIN Comparison
KZIA vs KXIN Comparison
Compare KZIA & KXIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- KXIN
- Stock Information
- Founded
- KZIA 1994
- KXIN 2015
- Country
- KZIA Australia
- KXIN China
- Employees
- KZIA N/A
- KXIN N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- KXIN Retail-Auto Dealers and Gas Stations
- Sector
- KZIA Health Care
- KXIN Consumer Discretionary
- Exchange
- KZIA Nasdaq
- KXIN Nasdaq
- Market Cap
- KZIA 9.0M
- KXIN 9.4M
- IPO Year
- KZIA 1999
- KXIN N/A
- Fundamental
- Price
- KZIA $8.04
- KXIN $0.61
- Analyst Decision
- KZIA Strong Buy
- KXIN
- Analyst Count
- KZIA 2
- KXIN 0
- Target Price
- KZIA $14.00
- KXIN N/A
- AVG Volume (30 Days)
- KZIA 17.4K
- KXIN 213.3K
- Earning Date
- KZIA 06-05-2025
- KXIN 01-01-0001
- Dividend Yield
- KZIA N/A
- KXIN N/A
- EPS Growth
- KZIA N/A
- KXIN N/A
- EPS
- KZIA N/A
- KXIN N/A
- Revenue
- KZIA $1,549,158.00
- KXIN N/A
- Revenue This Year
- KZIA N/A
- KXIN N/A
- Revenue Next Year
- KZIA $49.25
- KXIN N/A
- P/E Ratio
- KZIA N/A
- KXIN N/A
- Revenue Growth
- KZIA 248983.08
- KXIN N/A
- 52 Week Low
- KZIA $2.86
- KXIN $0.57
- 52 Week High
- KZIA $39.05
- KXIN $29.54
- Technical
- Relative Strength Index (RSI)
- KZIA 50.26
- KXIN 32.48
- Support Level
- KZIA $7.52
- KXIN $0.57
- Resistance Level
- KZIA $8.33
- KXIN $0.71
- Average True Range (ATR)
- KZIA 0.62
- KXIN 0.05
- MACD
- KZIA 0.04
- KXIN -0.01
- Stochastic Oscillator
- KZIA 67.93
- KXIN 19.28
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.